Neuralstem, Inc. (Nasdaq:CUR) announced on 8/9/18 that the U.S. Food and Drug Administration has granted orphan drug designation to NSI-189 for the... read more
Neuralstem, Inc. (Nasdaq:CUR) announced on 8/9/18 that the U.S. Food and Drug Administration has granted orphan drug designation to NSI-189 for the... read more
Ambys Medicines launched on 8/8/18 with a $60 million Series A financing funded by Third Rock Ventures and Takeda. As part of the launch, Ambys also announced today a strategic partnership with... read more
Clovis Oncology, Inc. (NASDAQ: CLVS) announced on 8/8/18 the randomization of the first patient in the Phase 3 ATHENA trial evaluating the combination of Clovis’ Rubraca (rucaparib), a... read more
With so many companies developing products related to the microbiome that include live microbes, we were curious about how companies are protecting their intellectual property. Since some... read more
Agilvax, Inc. announced on 8/7/18 the receipt of a Fast Track Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI). The grant will provide up to $2.3 million in... read more